ESR1 and breast carcinoma: The current study demonstrates that the sum of anti-estrogen actions can favorably immunomodulate the ER+ breast cancer TME in the context of RT, an established adjuvant and palliative treatment, even when these tumors no longer depend on estrogen for growth and are resistant to anti-estrogen monotherapy.